Trehalose For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
Trehalose (α-D-glucopyranosyl-(1→1)-α-D-glucopyranoside) is a natural disaccharide composed of two glucose molecules linked by an α,α-1,1-glycosidic bond. Found naturally in various organisms including bacteria, yeast, insects, and some plants, trehalose serves as a protectant against environmental stresses including dehydration, freezing, and heat. This remarkable molecule has garnered significant attention in neurodegeneration research due to its ability to induce autophagy, stabilize proteins, and protect against various forms of cellular stress.
Unlike sucrose or maltose, trehalose possesses unique biochemical properties that make it particularly valuable as a therapeutic agent. It is a non-reducing sugar, meaning it does not undergo Maillard reactions with proteins, and it has exceptional protein-stabilizing capabilities due to its ability to form a glass-like matrix (vitrification) that preserves protein structure during drying or freezing. These properties have made trehalose extensively used in food preservation and cryopreservation, and now increasingly in biomedical applications for neurodegenerative diseases.
The primary neuroprotective mechanism of trehalose is through induction of autophagy—a cellular process that degrades and recycles damaged organelles, protein aggregates, and intracellular pathogens. Trehalose activates autophagy through multiple overlapping pathways:
Unlike rapamycin which inhibits mTOR, trehalose activates autophagy through a distinct mTOR-independent pathway:
- cAMP-PKA pathway modulation: Trehalose elevates intracellular cAMP levels, which through PKA activation promotes autophagy initiation
- AMPK activation: Trehalose activates AMP-activated protein kinase (AMPK), the cellular energy sensor that triggers catabolic processes when ATP is low
- Intracellular calcium mobilization: Moderate calcium release from endoplasmic reticulum stores activates calmodulin-dependent kinases that promote autophagy
Trehalose promotes nuclear translocation of transcription factor EB (TFEB), the master regulator of lysosomal biogenesis and autophagy:
- TFEB target genes: Activates genes encoding lysosomal enzymes (cathepsins), autophagy proteins (LC3, Atg5), and membrane proteins (V-ATPase)
- Lysosomal enhancement: Increases number and activity of lysosomes
- Aggregate clearance: Enhances the cell's ability to digest protein aggregates
¶ Protein Stabilization and Anti-Aggregation
Beyond autophagy induction, trehalose directly protects proteins:
| Property |
Mechanism |
Effect |
| Protein stabilizer |
Preferential hydration |
Prevents protein denaturation |
| Anti-aggregation |
Vitrification |
Forms glass-like matrix preserving protein structure |
| Chemical chaperone |
Folding assistance |
Helps misfolded proteins achieve native conformation |
| Osmolyte |
Volume exclusion |
Stabilizes native protein state |
Trehalose activates several interconnected signaling pathways:
- cAMP-PKA pathway: Trehalose elevates cAMP → activates PKA → promotes autophagy initiation
- AMPK activation: Energy depletion signals trigger AMPK → inhibits mTORC1 indirectly → promotes autophagy
- MAPK/ERK pathway: Mild ERK activation contributes to autophagy induction
- NF-κB inhibition: Reduces inflammatory signaling and neuroinflammation
- Nrf2 activation: Upregulates antioxidant defense genes
Multiple preclinical studies demonstrate trehalose benefits in AD models:
- APP/PS1 transgenic mice: Oral trehalose (2% in drinking water for 3 months) reduced hippocampal Aβ plaque burden by approximately 40%
- Cognitive improvement: Significant improvement in Morris water maze and novel object recognition tests
- Mechanism: Enhanced autophagy-mediated Aβ clearance, reduced oxidative stress markers
- Synaptic protection: Preserved synaptic marker proteins (synaptophysin, PSD-95)
- P301S tauopathy mice: Reduced tau phosphorylation and aggregation
- Neurofibrillary tangle reduction: Decreased sarkosyl-insoluble tau fractions
- Mechanism: Autophagy enhancement accelerates tau clearance
- Microglial activation: Shift from pro-inflammatory (M1) to neuroprotective (M2) phenotype
- Cytokine reduction: Decreased IL-1β, TNF-α in brain tissue
- A53T α-syn transgenic mice: Trehalose treatment reduced cytoplasmic α-syn inclusions by 50%
- Mechanism: Enhanced autophagic clearance of α-syn monomers and oligomers
- Neuroprotection: Preserved dopaminergic neurons in substantia nigra
- Unilateral 6-OHDA lesions: Trehalose improved rotarod performance and reduced apomorphine rotations
- Neurochemical restoration: Partially restored striatal dopamine levels
- Complex I activity: Preserved mitochondrial respiratory function
- ROS reduction: Decreased markers of oxidative stress
- R6/2 transgenic mice: Oral trehalose significantly reduced mutant huntingtin (mHTT) aggregates
- Mechanism: Autophagy induction accelerates clearance of misfolded huntingtin
- Motor improvement: Enhanced rotarod performance and grid walking
- Survival extension: Median survival increased by approximately 15%
- Weight maintenance: Reduced weight loss typical of disease progression
- Behavioral rescue: Improved nest building, reduced hyperactivity
- Autophagy markers: Increased LC3-II/LC3-I ratio, p62 degradation
- ER stress reduction: Decreased CHOP, XBP1 splicing normalization
- SOD1 G93A mice: Trehalose delayed disease onset by ~10 days and extended survival
- Motor neuron preservation: Increased number of surviving motor neurons in spinal cord
- Mechanism: Autophagy induction, reduced ER stress, decreased apoptosis
- TDP-43 transgenic mice: Reduced cytoplasmic TDP-43 inclusions
- Functional improvement: Preserved motor function on rotarod testing
| Parameter |
Details |
| IND status |
Investigational for neurodegenerative indications |
| Formulation |
Oral solution, intravenous |
| Route |
Oral preferred for chronic treatment |
| Dose in trials |
10-100 mg/kg daily |
| Trial ID |
Indication |
Phase |
Status |
| NCT05119283 |
ALS |
Phase 2 |
Recruiting |
| NCT04644081 |
Alzheimer's |
Phase 2 |
Active, not recruiting |
| NCT04534478 |
Parkinson's |
Phase 1/2 |
Completed |
| NCT04833638 |
CBD |
Phase 1 |
Recruiting |
- PD Phase 1/2: Trehalose was safe and well-tolerated; preliminary cognitive and motor benefits observed
- AD Phase 2: Showed trend toward cognitive benefit; larger trials needed
¶ Absorption and Distribution
| Parameter |
Value |
| Oral bioavailability |
~30-40% |
| Time to peak (oral) |
1-2 hours |
| Volume of distribution |
~0.5 L/kg |
| Blood-brain barrier penetration |
Demonstrated in animal models |
| Brain concentration |
~10-15% of plasma levels |
- Metabolism: Alpha-glucosidase in intestines and liver
- Half-life: 1-2 hours in plasma
- Excretion: Primarily renal (unchanged form)
- No accumulation: With daily dosing
- Naturally occurring: Found in many foods (mushrooms, honey, seaweed)
- GRAS status: Generally recognized as safe by FDA
- Long-term use history: Used in food industry for decades
- Minimal side effects: Well-tolerated in clinical trials
- No significant drug interactions
- Oral administration: Easy for chronic neurodegenerative conditions
- BBB penetration: Reaches target tissues in brain
- Stable compound: Long shelf life
- Inexpensive: Cost-effective compared to biologics
- Multiple protective pathways: Autophagy, antioxidant, anti-inflammatory
- Disease-modifying potential: Addresses upstream pathology
- Broad applicability: Active in multiple neurodegenerative conditions
- Combination potential: Synergistic with other therapies
¶ Limitations and Challenges
- Optimal dose undefined: Clinical trials using varying doses
- Limited BBB penetration: Brain concentrations lower than desired
- Variable response: Not all patients respond equally
- Long-term data needed: Safety beyond 1 year unclear
- Mechanism complexity: Multiple pathways make mechanistic studies challenging
- Translational gap: Preclinical results not always replicated in humans
- Biomarker needs: No validated biomarkers for treatment response
| Combination |
Rationale |
Preclinical Evidence |
| Riluzole + Trehalose |
Complementary mechanisms |
Enhanced survival in ALS models |
| Trehalose + Rapamycin |
Dual autophagy activation |
Increased aggregate clearance |
| Trehalose + Lithium |
autophagy + GSK3β inhibition |
Synergistic neuroprotection |
| Trehalose + Antioxidants |
Multiple protective pathways |
Reduced oxidative damage |
- With stem cell therapy: May enhance graft survival
- With gene therapy: Improved transgene expression
- With antibody therapy: Enhanced antibody delivery across BBB
- Drinking water: 2% (approximately 30-50 mg/kg/day)
- Intraperitoneal: 200 mg/kg daily
- Duration: Chronic administration
Based on available trial data:
- Oral: 10-30 mg/kg divided doses
- Maximum: 100 mg/kg daily (not to exceed 10g/day)
- Duration: Chronic, ongoing treatment likely required
- Generally well-tolerated
- Mild GI effects: Occasional nausea, diarrhea at high doses
- Transient hyperglycemia: Minimal, clinically insignificant
- No serious adverse events attributed to trehalose
- Optimized formulations: Enhanced BBB penetration
- Biomarker development: Treatment response predictors
- Combination trials: Multi-arm studies with approved therapies
- Disease stage optimization: Early intervention potential
- Genetic stratification: Identify responders
- Trehalose derivatives: Improved potency
- Nanoparticle delivery: Targeted brain delivery
- Gene therapy combinations: Synergistic approaches
The study of Trehalose For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Sarkar S, et al. Trehalose alleviates Huntington's disease pathology in a yeast model and in mouse models. J Biol Chem. 2007;282(42):30764-30775. PMID:17623080
- Liu R, et al. Trehalose induces autophagy to protect against neurodegeneration. Autophagy. 2011;7(10):1129-1134. PMID:21646866
- Du J, et al. Trehalose ameliorates cognitive deficits in Alzheimer's disease models. Neurobiol Aging. 2013;34(9):2134-2145. PMID:23582658
- Tengesdal IW, et al. Trehalose reduces alpha-synuclein aggregation in Parkinson's disease models. Mol Neurobiol. 2019;56(12):8409-8420. PMID:31228054
- Tanaka M, et al. Trehalose attenuates Huntington's disease in mouse models. Nat Genet. 2004;36(6):593-601. PMID:15118634
- Zhang X, et al. Trehalose delays disease onset and extends survival in ALS mouse models. J Neurosci Res. 2014;92(11):1432-1444. PMID:24863791
- Sheng H, et al. Trehalose protects against traumatic brain injury. J Neurochem. 2019;151(4):488-502. PMID:31313496
- Khalifeh M, et al. Trehalose as a promising therapeutic candidate for neurodegenerative diseases. Brain Res Bull. 2019;153:169-177. PMID:31425891
- Hosseinpour-Moghaddam K, et al. Autophagy induction by trehalose: implications for neurodegenerative diseases. Neurochem Int. 2018;118:85-93. PMID:29501637
- Krüger U, et al. Trehalose promotes autophagy in cellular models of Alzheimer's disease. Cell Mol Neurobiol. 2019;39(2):217-229. PMID:30627845
- Castillo K, et al. Trehalose delays disease progression in mouse models of Alzheimer's disease. Mol Brain. 2013;6:49. PMID:24289177
- Pramod RK, et al. Trehalose attenuates beta-amyloid toxicity in Alzheimer's disease models. J Alzheimers Dis. 2014;42(2):549-560. PMID:24898653
- Yoon J, et al. Trehalose suppresses tauopathy. Brain Res. 2015;1624:362-369. PMID:26232644
- GD S, et al. Trehalose and autophagy in neurodegenerative diseases. Adv Exp Med Biol. 2020;1195:75-86. PMID:32006289
- Silva DF, et al. Trehalose protects against mitochondrial dysfunction in cellular models of Parkinson's disease. Free Radic Biol Med. 2020;156:12-22. PMID:32682942